GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports that it has repurchased 345,000 ordinary shares of 31¼ pence each on 26 March 2026 through BNP Paribas under its existing share buyback programme. The shares were bought at prices between 2,037.00p and 2,072.00p, with a volume‑weighted average price of 2,053.34p per share.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought a total of 15,201,521 ordinary shares. After this transaction, GSK holds 255,092,615 shares in treasury and has 4,061,083,663 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.28% of voting rights.
GSK plc reports that the European Medicines Agency has accepted for review a marketing authorisation application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. The submission is backed by Phase III B‑Well 1 and B‑Well 2 trials, which met their primary endpoint and showed statistically significant, clinically meaningful functional cure rates versus standard of care.
Chronic hepatitis B affects an estimated 3.2 million people in Europe and more than 250 million worldwide, with current nucleos(t)ide analogue therapies often requiring lifelong treatment and achieving functional cure in only about 1% of patients. Bepirovirsen is designed to target hepatitis B viral RNA, reduce hepatitis B surface antigen, and stimulate the immune system, with trials indicating an acceptable safety and tolerability profile. The data will be presented at a scientific congress and submitted for peer‑reviewed publication in 2026, while bepirovirsen remains unapproved globally.
GSK plc reports that on 25 March 2026 it repurchased 345,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 1,988.50p to 2,047.00p per share, with a volume‑weighted average price of 2,033.20p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought a total of 14,856,521 ordinary shares. After this transaction, it holds 254,747,615 shares in treasury and has 4,061,428,663 ordinary shares in issue, which is also the total number of voting rights.
The company states that, in line with DTR 5.5.1R, treasury shares represent 6.27% of the voting rights. Detailed schedules list the number of shares and prices per trade across London Stock Exchange and Cboe Europe venues.
GSK plc reported an executive share-related transaction involving President Maya Martinez-Davis. She acquired 6.679 notional American Depositary Shares in her GSK Executive Supplemental Savings Plan account at a price of $51.9900 per ADS. The transaction took place on 23 March 2026 on the New York Stock Exchange.
GSK plc has released the Notice of Annual General Meeting 2026 on its website and will send it to shareholders. The AGM is scheduled for 6 May 2026 at 2:30pm at the London Marriott Hotel Grosvenor Square and will also be broadcast live for shareholders to join electronically. Related documents, including the 2026 AGM Notice, Proxy Form, and marked-up Articles of Association showing proposed changes, will be submitted to the UK Financial Conduct Authority for inspection via its National Storage Mechanism.
GSK plc reports that on 24 March 2026 it repurchased 500,000 ordinary shares of 31¼ pence each through BNP Paribas as part of its existing share buyback programme. The shares were bought at prices between 1,933.00p and 1,967.00p, with a volume-weighted average price of 1,949.05p per share.
The repurchased shares will be held as treasury shares. Since 17 February 2026, the company has bought back 14,511,521 ordinary shares. After this latest transaction, GSK holds 254,402,615 shares in treasury and has 4,061,773,663 ordinary shares in issue, which is also the total number of voting rights. The company states that treasury shares represent 6.26% of voting rights.
GSK plc reports that on 23 March 2026 it bought 680,000 of its ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were purchased at prices between 1,906.50p and 1,964.50p, with a volume‑weighted average price of 1,937.07p per share, and will be held as treasury shares.
Since 17 February 2026, GSK has bought 14,011,521 ordinary shares in total. Following this latest transaction, it holds 253,902,615 ordinary shares in treasury and has 4,062,273,663 ordinary shares in issue, which is also the total number of voting rights. The company states that, after this purchase, 6.25 per cent of its voting rights are attributable to treasury shares.
GSK plc reported multiple open‑market share purchases by its chair and non-executive directors. On 20 March 2026, Non-Executive Chair Sir Jonathan Symonds bought 5,000 ordinary shares at an average price of £19.5111 on the London Stock Exchange.
Independent director Wendy Becker bought 411 ordinary shares at £19.6250, while several other independent directors, including Elizabeth McKee Anderson and Charles Bancroft, purchased American Depositary Shares on the New York Stock Exchange at $51.7939 per ADS. Additional directors such as Dr Gavin Screaton and Dr Vishal Sikka also acquired ordinary shares or ADS in similar-sized transactions.
GSK plc reported that an additional 96,525 ordinary shares of 31¼ pence each have been admitted to trading on the London Stock Exchange Main Market. These shares were issued under existing block listings connected to the GlaxoSmithKline plc Share Save Plan 2012 and 2022.
Following this admission, the total number of GSK ordinary shares admitted to trading is 4,316,176,278, fully fungible with existing shares. The notification covers activity between 23 January 2026 and 20 March 2026 and was signed by Company Secretary Victoria Whyte.
GSK plc reported that its investigational B7-H3‑targeted antibody‑drug conjugate risvutatug rezetecan (Ris‑Rez) has received Orphan Drug Designation in Japan for treating small‑cell lung cancer. The decision by Japan's Ministry of Health, Labour and Welfare is based on preliminary phase I ARTEMIS‑001 data showing durable responses in extensive‑stage small‑cell lung cancer.
This is the sixth global regulatory designation for Ris‑Rez, which is being developed for multiple solid tumours, including lung, prostate and colorectal cancers. GSK has already started a global phase III trial (NCT07099898) in relapsed extensive‑stage small‑cell lung cancer, which began in August 2025, alongside prior US FDA and European EMA designations.